Номер части:
ISSN: 2411-6467 (Print)
ISSN: 2413-9335 (Online)
Статьи, опубликованные в журнале, представляется читателям на условиях свободной лицензии CC BY-ND


Науки и перечень статей вошедших в журнал:
DOI: 10.31618/ESU.2413-9335.2020.1.77.959
Дата публикации статьи в журнале: 2020/09/16
Название журнала: Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале, Выпуск: 77, Том: 1, Страницы в выпуске: 11-20
Автор: Izrailbekova K.
, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan ,
Анотация: Breast cancer (BC ) is the most common cancer among women, and current treatments available often have high success rates. However, BC can acquire drug resistance and sometimes relapse. Current knowledge about the most aggressive forms of BC indicates the role of specific cells with stem properties located in BC, the so-called "BCSCs" (Brest cancer stem cells). The role of BCSCs in cancer formation, growth, invasiveness, therapy resistance, and tumor recurrence is becoming increasingly evident. The growth and metastatic properties of BCSCs are regulated in a variety of ways that are only partially known. Sex steroid receptors (SSRs), which are involved in the etiology and progression of BC, promote the proliferation, dedifferentiation and migration of BCSCs. However, the literature contains incomplete information about their roles. In particular, there are conflicting findings regarding the expression and role of classic BC hormone biomarkers such as estrogen receptor alpha (ERα), together with scanty, albeit promising, information on the properties of ER-beta (ERβ) and androgen receptor (AR) that control pathways of transduction in BCSC. In this review, we will discuss the role that SRs expressed in BCSCs play in BC progression and relapse, and how these findings have opened up new therapeutic options. These cells are predictors of BC and promising new therapies are being developed to target these cells and improve BC recurrence.
Ключевые слова: breast cancer, Steroids,Sex steroid receptors,Cancer stem cells,Therapeutic implications ,
Данные для цитирования: Izrailbekova K. . STEM CELLS IN BREAST CANCER: THE ROLE OF GENDER STEROID RECEPTORS (11-20) // Евразийский Союз Ученых — публикация научных статей в ежемесячном научном журнале. Медицинские науки. 2020/09/16; 77(1):11-20. 10.31618/ESU.2413-9335.2020.1.77.959

Список литературы: 1.Acconcia F, Kumar R. Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 2006; 238: 1-14 [PMID: 16084012 DOI: 10.1016/j.canlet.2005.06.018] 2.Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988 [PMID: 12629218 DOI:10.1073/pnas.0530291100] 3.Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE. Control of mammary stem cell function by steroid hormone signaling. Nature 2010; 465: 798-802 [PMID: 20383121 DOI: 10.1038/nature09027] 4.Bado I, Gugala Z, Fuqua SAW, Zhang XH. Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis. Oncogene 2017; 36: 4527-4537 [PMID: 28368409 DOI:10.1038/onc.2017.94] 5. Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK. Androgen Receptor Supports an AnchorageIndependent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. Cancer Res 2017; 77: 3455-3466 [PMID:28512248 DOI: 10.1158/0008- 5472.CAN-16-3240] 6.Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm 7.Bartucci M, Dattilo R, Moriconi C, Pagliuca A, Mottolese M, Federici G, Benedetto AD, Todaro M, Stassi G, Sperati F, Amabile MI, Pilozzi E, Patrizii M, Biffoni M, Maugeri-Saccà M, Piccolo S, De Maria R. TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 2015; 34: 681-690 [PMID: 24531710 DOI: 10.1038/onc.2014.5] 8.Bullock LP, Bardin CW, Sherman MR. Androgenic, antiandrogenic, and synandrogenic actions of progestins: role of steric and allosteric interactions with androgen receptors. Endocrinology 1978; 103:1768-1782 [PMID: 748017 DOI: 10.1210/endo- 103-5-1768] 9.Cancer 2015; 6: 206-213 [PMID: 26201402 DOI: 10.1007/s12672-015-0232-3] 10.Castoria G, Auricchio F, Migliaccio A. Extranuclear partners of androgen receptor: at the crossroads of proliferation, migration, and neuritogenesis. FASEB J 2017; 31: 1289-1300 [PMID: 28031322 DOI:10.1096/fj.201601047R] 11. Castoria G, Giovannelli P, Lombardi M, De Rosa C, Giraldi T, de Falco A, Barone MV, Abbondanza C, Migliaccio A, Auricchio F. Tyrosine phosphorylation of estradiol receptor by Src regulates its hormonedependent nuclear export and cell cycle progression in breast cancer cells. Oncogene 2012; 31: 4868-4877 [PMID: 22266855 DOI: 10.1038/onc.2011.642] 12. Castoria G, Migliaccio A, D'Amato L, Di Stasio R, Ciociola A, Lombardi M, Bilancio A, Di Domenico M, de Falco A, Auricchio F. Integrating signals between cAMP and MAPK pathways in breast cancer. Front Biosci 2008; 13: 1318-1327 [PMID: 17981632 DOI: 10.2741/2764] 13. Castoria G, Migliaccio A, Giovannelli P, Auricchio F. Cell proliferation regulated by estradiol receptor:Therapeutic implications. Steroids 2010; 75: 524-527 [PMID: 19879889 DOI: 10.1016/j.steroids.2009.10.007] 14. Chang C, Yeh S, Lee SO, Chang TM. Androgen receptor (AR) pathophysiological roles in androgenrelated diseases in skin, bone/muscle, metabolic syndrome and neuron/immune systems: lessons learned from mice lacking AR in specific cells. Nucl Recept Signal 2013; 11: e001 [PMID: 24653668 DOI:10.1621/nrs.11001] 15.Charafe-Jauffret E, Ginestier C, Birnbaum D. Cancer stem cells: just sign here! Cell Cycle 2010; 9: 229-230 [PMID: 20061794 DOI: 10.4161/cc.9.2.10669] 16. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014; 16: R7 [PMID: 24451109 DOI: 10.1186/bcr3599] 17. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S, Piccolo S. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011; 147: 759-772 [PMID: 22078877 DOI: 10.1016/j.cell.2011.09.048] 18. Crabtree JS, Miele L. Breast Cancer Stem Cells. Biomedicines 2018; 6 [PMID: 30018256 DOI:10.3390/biomedicines6030077] 19. Davis PJ, Lin HY, Mousa SA, Luidens MK, Hercbergs AA, Wehling M, Davis FB. Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Steroids 2011; 76: 829-833 [PMID: 21354437 DOI: 10.1016/j.steroids.2011.02.012] 20. Di Donato M, Giovannelli P, Cernera G, Di Santi A, Marino I, Bilancio A, Galasso G, Auricchio F, Migliaccio A, Castoria G. Non-genomic androgen action regulates proliferative/migratory signaling in stromal cells. Front Endocrinol (Lausanne) 2015; 5: 225 [PMID: 25646090 DOI:10.3389/fendo.2014.00225] 21. Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Castoria G. Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications. Front Oncol 2018; 8: 2 [PMID: 29404276 DOI:10.3389/fonc.2018.00002] 22. Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Di Santi A, Cernera G, Rossi V, Abbondanza C, Moncharmont B, Sinisi AA, Castoria G, Migliaccio A. Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget 2016; 7: 193-208 [PMID: 26506594 DOI: 10.18632/oncotarget.6220] 23. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36 Suppl 1: 59-72 [PMID: 14521516 DOI: 10.1046/j.1365- 2184.36.s.1.6.x] 24. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004; 15: 193-197 [PMID: 15223047 DOI: 10.1016/j.tem.2004.05.011] 25.Faivre EJ, Lange CA. Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 2007; 27: 466-480 [PMID: 17074804] 26. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, Liu B, Lei Y, Du S, Vuppalapati A, Luu HH, Haydon RC, He TC, Ren G. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 2018; 5: 77-106 [PMID: 30258937 DOI: 10.1016/j.gendis.2018.05.001] 27. Finlay-Schultz J, Sartorius CA. Steroid hormones, steroid receptors, and breast cancer stem cells. J Mammary Gland Biol Neoplasia 2015; 20: 39- 50 [PMID: 26265122 DOI: 10.1007/s10911-015-9340-5] 28. Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 1999; 54: 291-313; discussion 313-4 [PMID: 10548881] 29. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1:555- 567 [PMID: 18371393 DOI: 10.1016/j.stem.2007.08.014] 30.Giovannelli P, Di Donato M, Auricchio F, Castoria G, Migliaccio A. Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly. Sci Rep 2019; 9: 4490 [PMID: 30872694 DOI: 10.1038/s41598- 019-41016-4] 31. Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Bilancio A, Migliaccio A. The Androgen Receptor in Breast Cancer. Front Endocrinol (Lausanne) 2018; 9: 492 [PMID: 30210453 DOI: 10.3389/fendo.2018.00492] 32. Giovannelli P, Di Donato M, Giraldi T, Migliaccio A, Castoria G, Auricchio F. Targeting rapid action of sex steroid receptors in breast and prostate cancers. Front Biosci (Landmark Ed) 2011; 16: 2224- 2232 [PMID: 21622172 DOI: 10.2741/3849] 33. Giraldi T, Giovannelli P, Di Donato M, Castoria G, Migliaccio A, Auricchio F. Steroid signaling activation and intracellular localization of sex steroid receptors. J Cell Commun Signal 2010; 4: 161- 172 [PMID: 21234121 DOI: 10.1007/s12079-010-0103-1] 34. Goodman CR, Sato T, Peck AR, Girondo MA, Yang N, Liu C, Yanac AF, Kovatich AJ, Hooke JA, Shriver CD, Mitchell EP, Hyslop T, Rui H. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene 2016; 35: 1373-1385 [PMID: 26096934 DOI: 10.1038/onc.2015.193] 35.Graham JD, Clarke CL. Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells. Breast Cancer Res 2002; 4: 187-190 [PMID: 12223122 DOI:10.1186/bcr450] 36. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008; 26: 3727-3734 [PMID: 18669459 DOI: 10.1200/JCO.2007.14.2968] 37. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 2008; 93: 3295- 3298 [PMID: 18647813 DOI: 10.1210/jc.2008-0938] 38. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012; 2012: 708036 [PMID: 22693526 DOI: 10.1155/2012/708036] 39. Kakarala M, Wicha MS. Cancer stem cells: implications for cancer treatment and prevention. Cancer J 2007; 13: 271-275 [PMID: 17921723 DOI: 10.1097/PPO.0b013e318156da4e] 40. Kamishov S.V. Mechanisms of immune disorders in patients with ovarian cancer receiving chemotherapy and their dynamics during immunotherapy // Eurasian Oncological Journal, -2018 -P. 563-576 41. Kamishov S.V. Modern immunopharmacotherapy in the complex treatment of cervical cancer // Bulletin of Science and Education - 2018 -V.2 (6 (42)), -P. 57-61 42. Kamishov S.V., Pulatov D.A., Nishanov D.A., Yuldasheva N.Sh. Influence of the expression level of tumor markers on the results of treatment of patients with cervical cancer who received concomitant immunotherapy // Eurasian Oncological Journal 5 (1), - 2017-P. 68-76 43. Kamishov S.V., Pulatov D.A., Yusupova N.B., Niezova Sh.Kh. The state of immunoreactivity of patients with cervical cancer against the background of extracorporeal immunopharmacotherapy // Bulletin of the National. medical surgeon. center them. N.I. Pirogov 13 (1), -P. 98-102 44. Kamishov S.V., Pulatov D.A.Supportive immunotherapy in complex treatment of patients with oncogynaecological diseases //The scientific heritage - 2017 -V.18 (18), 23-27 45.Kamyshov S.V., Nishanov D.A., Pulatov D.A., Yuldasheva N.S. //Izuchenie markerov apoptoza, proliferacii i angiogeneza u bol'nyh rakom jaichnika, poluchivshih soprovoditel'nuju immunoterapiju [The study of markers of apoptosis, proliferation and angiogenesis in patients with ovarian cancer who received accompanying immunotherapy]. Zlokachestvennye opuholi [Malignant tumors], 1, 84-91 46. Kamyshov S.V., Pulatov D.A., Nishanov D.A., Yuldasheva N.S., Yusupova N.B. Znachimost'ocenki molekuljarno-biologicheskih onkomarkerov v soprovoditel'noj immunoterapii pri rake shejki matki [Significance of the assessment of molecular biological tumor markers in accompanying immunotherapy for cervical cancer]. Onkologija i radiologija Kazahstana [Oncology and radiology of Kazakhstan], 2017 V.2 -P. 45-48 47. Kamyshov S.V., Pulatov D.A., Yuldasheva N.S. Ispol'zovanie metodov gravitacionnoj hirurgii krovi v kompleksnom lechenii bol'nyh rakom jaichnika [The use of gravitational blood surgery methods in the complex treatment of patients with ovarian cancer]. Vestnik Nacional'nogo mediko-hirurgicheskogo centra im. NI Pirogova BBBulletin of the National Medical and Surgical Center after Ni Pirogov], -201712 (1), -P. 52-56 48. Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, Roloff T, Britschgi A, Eichlisberger T, Kohler H, Aina O, Cardiff RD, Bentires-Alj M. PIK3CA(H1047R) induces multipotency and multilineage mammary tumours. Nature 2015; 525: 114-118 [PMID: 26266975 DOI: 10.1038/nature14669] 49. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011; 121: 3804-3809 [PMID: 21965337 DOI: 10.1172/JCI57099] 50. Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Moriya T. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells. Breast Cancer 2016; 23: 425-436 [PMID: 25552385 DOI: 10.1007/s12282-014-0580-9] 51.Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem Cells 2012; 30: 833-844 [PMID: 22489015 DOI: 10.1002/stem.1058] 52.Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011; 10: 47-60 [PMID: 21193867 DOI: 10.1038/nrd3320] 53.Lauricella M, Carlisi D, Giuliano M, Calvaruso G, Cernigliaro C, Vento R, D'Anneo A. The analysis of estrogen receptor-α positive breast cancer stem-like cells unveils a high expression of the serpin proteinase inhibitor PI-9: Possible regulatory mechanisms. Int J Oncol 2016; 49: 352-360 [PMID: 27121069 DOI: 10.3892/ijo.2016.3495] 54.LeBedis C, Chen K, Fallavollita L, Boutros T, Brodt P. Peripheral lymph node stromal cells can promote growth and tumorigenicity of breast carcinoma cells through the release of IGF-I and EGF. Int J Cancer 2002; 100: 2-8 [PMID: 12115579 DOI: 10.1002/ijc.10481] 55.Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 2008; 28: 479-483 [PMID: 18383888] 56.Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2010; 28: 4006-4012 [PMID:20498387 DOI: 10.1200/JCO.2009.27.5388] 57.Lyu S, Yu Q, Ying G, Wang S, Wang Y, Zhang J, Niu Y. Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer. Int J Oncol 2014; 44: 229- 237 [PMID: 24172884 DOI: 10.3892/ijo.2013.2151] 58.Ma R, Karthik GM, Lövrot J, Haglund F, Rosin G, Katchy A, Zhang X, Viberg L, Frisell J, Williams C, Linder S, Fredriksson I, Hartman J. Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells. J Natl Cancer Inst 2017; 109: 1-14 [PMID: 28376210 DOI: 10.1093/jnci/djw236] 59.Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, Tamaki Y, Terada N, Noguchi S. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009; 100: 1062-1068 [PMID: 19385968 DOI: 10.1111/j.1349-7006.2009.01151.x] 60. Nandy SB, Gangwani L, Nahleh Z, Subramani R, Arumugam A, de la Rosa JM, Lakshmanaswamy R. Recurrence and metastasis of breast cancer is influenced by ovarian hormone's effect on breast cancer stem cells. Future Oncol 2015; 11: 983-995 [PMID: 25760978 DOI: 10.2217/fon.14.301] 61. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277: 1508-1510 [PMID: 9278514 DOI: 10.1126/science.277.5331.1508] 62. Palomeras S, Ruiz-Martínez S, Puig T. Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance. Molecules 2018; 23 [PMID: 30200262 DOI: 10.3390/molecules23092193] 63. Poli V, Fagnocchi L, Fasciani A, Cherubini A, Mazzoleni S, Ferrillo S, Miluzio A, Gaudioso G, Vaira V, Turdo A, Gaggianesi M, Chinnici A, Lipari E, Bicciato S, Bosari S, Todaro M, Zippo A. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. Nat Commun 2018; 9: 1024 [PMID: 29523784 DOI: 10.1038/s41467-018-03264-2] 64. Proc Natl Acad Sci U S A 2006; 103: 9063- 9068 [PMID: 16754886 DOI: 10.1073/pnas.0603339103] 65.Pulatov D.A., Ibragimov Zh.M., Kamishov S.V. Comparative assessment of the toxicity of treatment of patients with chemoresistant colorectal cancer // Oncology and Radiology of Kazakhstan -2018 V.44 (2), -P. 58-61 66. Riaz N, Idress R, Habib S, Azam I, Lalani EM. Expression of Androgen Receptor and Cancer Stem Cell Markers (CD44+/CD24- and ALDH1+): Prognostic Implications in Invasive Breast Cancer. Transl Oncol 2018; 11: 920-929 [PMID: 29843115 DOI: 10.1016/j.tranon.2018.05.002] 67. Riobo-Del Galdo A, Lara Montero Á, Wertheimer EV. Role of Hedgehog Signaling in Breast Cancer: Pathogenesis and Therapeutics. Cells 2019; 8 [PMID: 31027259 DOI: 10.3390/cells8040375] 68. Rosin G, de Boniface J, Karthik GM, Frisell J, Bergh J, Hartman J. Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis. Br J Cancer 2014; 111: 918-926 [PMID: 25025959 DOI: 10.1038/bjc.2014.398] 69. Rossi V, Di Zazzo E, Galasso G, De Rosa C, Abbondanza C, Sinisi AA, Altucci L, Migliaccio A, Castoria G. Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells. Front Pharmacol 2019; 10: 28 [PMID: 30828298 DOI:10.3389/fphar.2019.00028] 70.Rudland PS, Barraclough R, Fernig DG, Smith JA. Growth and differentiation of the normal mammary gland and its tumours. Biochem Soc Symp 1998; 63: 1- 20 [PMID: 9513707] 71. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011; 29: 3651-3658 [PMID: 21859989 DOI: 72. Schabath H, Runz S, Joumaa S, Altevogt P. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 2006; 119: 314- 325 [PMID: 16390867 DOI: 10.1242/jcs.02741] 73. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30 [PMID: 26742998 DOI: 10.3322/caac.21332] 74. Simões BM, O'Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, Alférez DG, Spence K, SantiagoGómez A, Chemi F, Acar A, Gandhi A, Howell A, Brennan K, Rydén L, Catalano S, Andó S, Gee J, Ucar A, Sims AH, Marangoni E, Farnie G, Landberg G, Howell SJ, Clarke RB. Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. Cell Rep 2015; 12: 1968-1977 [PMID: 26387946 DOI: 10.1016/j.celrep.2015.08.050] 75.Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, Hirtenlehner K, Seifert M, Kubista E. MMP2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromalepithelial interactions. Breast Cancer Res Treat 2002; 72: 69-77 [PMID: 12000221 DOI:10.1023/A:1014918512569] 76. Tillyashaikhov M.N., Kamishov S.V. Features of the cellular status of immunity in patients with cervical cancer European science, 2018 No. 5 (37) P.75-79. 77. Tillyashaikhov M.N., Kamishov S.V. Features of the humoral status of immunity in patients with cervical cancer // Materials of the conference International scientific review of the problems and prospects of modern science and education 2018 -p. 84- 87 78. Truong TH, Dwyer AR, Diep CH, Hu H, Hagen KM, Lange CA. Phosphorylated Progesterone Receptor Isoforms Mediate Opposing Stem Cell and Proliferative Breast Cancer Cell Fates. Endocrinology 2019; 160: 430-446 [PMID: 30597041 DOI: 10.1210/en.2018-00990] 79. Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: djt319 [PMID: 24273215 DOI:10.1093/jnci/djt319] 80. Vicent GP, Ballaré C, Nacht AS, Clausell J, Subtil-Rodríguez A, Quiles I, Jordan A, Beato M. Convergence on chromatin of non-genomic and genomic pathways of hormone signaling. J Steroid Biochem Mol Biol 2008; 109: 344-349 [PMID: 18417338 DOI: 10.1016/j.jsbmb.2008.03.015] 81. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. A variant of estrogen receptor-{alpha}, hER{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. 82. Warner M, Huang B, Gustafsson JA. Estrogen Receptor β as a Pharmaceutical Target. Trends Pharmacol Sci 2017; 38: 92-99 [PMID: 27979317 DOI: 10.1016/j.tips.2016.10.006]

Записи созданы 9819

Похожие записи

Начните вводить, то что вы ищите выше и нажмите кнопку Enter для поиска. Нажмите кнопку ESC для отмены.

Вернуться наверх
404: Not Found404: Not Found